Abstract
High grade serous (HGS) cancer of the ovary (OC) is a lethal malignancy with advanced stage disease remaining incurable. HGS OC is sensitive to platinum based chemotherapy with complete responses being frequent, but relapses are inevitable, with resistance invariably emerging. Deeper understanding of the pathogenesis of HGS OC with new sequencing techniques shows that aberrations in the BRCA pathway may play a major role. Changes in the homologous recombination pathway and DNA repair may play a role in platinum resistance. This review article describes various approaches that have been studied in the management of chemotherapy resistance in HGS OC including Poly ADPribose polymerase (PARP) inhibition, Wee1 inhibition, epigenetic agents, immunotherapy and angiogenesis targeting agents.
Keywords: Chemotherapy, high grade serous, ovarian, resistance.
Graphical Abstract
Current Cancer Therapy Reviews
Title:Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Volume: 12 Issue: 1
Author(s): Raghav Sundar, David Tan, Lim S. Lei and Whay-Kuang Chia
Affiliation:
Keywords: Chemotherapy, high grade serous, ovarian, resistance.
Abstract: High grade serous (HGS) cancer of the ovary (OC) is a lethal malignancy with advanced stage disease remaining incurable. HGS OC is sensitive to platinum based chemotherapy with complete responses being frequent, but relapses are inevitable, with resistance invariably emerging. Deeper understanding of the pathogenesis of HGS OC with new sequencing techniques shows that aberrations in the BRCA pathway may play a major role. Changes in the homologous recombination pathway and DNA repair may play a role in platinum resistance. This review article describes various approaches that have been studied in the management of chemotherapy resistance in HGS OC including Poly ADPribose polymerase (PARP) inhibition, Wee1 inhibition, epigenetic agents, immunotherapy and angiogenesis targeting agents.
Export Options
About this article
Cite this article as:
Sundar Raghav, Tan David, Lei S. Lim and Chia Whay-Kuang, Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160609121238
DOI https://dx.doi.org/10.2174/1573394712666160609121238 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine The Effects of Trifluoromethylated Derivatives on Prostaglandin E<sub>2</sub> and Thromboxane A<sub>2</sub> Production in Human Leukemic U937 Macrophages
Medicinal Chemistry Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Pharmaceutical Nanotechnology United States Patent Watch (October – December 2014)
Pharmaceutical Nanotechnology Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Diagnosis and Treatment of Breast, Ovarian and Cervical Cancers
Current Drug Metabolism Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology High Expression of miR-206 Predicts Adverse Outcomes: A Potential Therapeutic Target for Esophageal Cancer
Combinatorial Chemistry & High Throughput Screening Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets